Use of a Blast Dominance–Hematogone Index for the Flow Cytometric Evaluation of Myelodysplastic Syndrome (MDS)

Online journal article in Hematopathology that offers 1.0 continuing education (CME/SAM) credit that can be used to fulfill CC Part II requirements.

Quantity:

Want to save more?

Log into see if you qualify for a lower rate.

Members

save $5.00 or more

Intended Audience: Pathologists, Residents, Clinical Scientists, Pathologist Assistants

Upon completion of this activity, you will be able to:

describe the historical limitations of flow cytometry in diagnosing myelodysplastic syndrome (MDS).
define the key immunophenotypic markers used to track...

Intended Audience: Pathologists, Residents, Clinical Scientists, Pathologist Assistants

Upon completion of this activity, you will be able to:

describe the historical limitations of flow cytometry in diagnosing myelodysplastic syndrome (MDS).
define the key immunophenotypic markers used to track CD34+ blast heterogeneity and hematogone frequency and how both are altered in MDS.
discuss the advantages and limitations of the blast dominance-hematogone index in diagnosing MDS, especially when compared with previous flow cytometric methods.

View More View Less